Skip to search formSkip to main contentSkip to account menu

AXL1717

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

picropodophyllin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation… 
2017
2017
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer
Abstract Background: The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between… 
2017
2017
The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a…
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and… 
2015
2015
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or…
Abstract AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The… 
2014
2014
Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung…
8091 Background: AXL1717 (picropodophyllin) is small molecule that inhibits the IGF-1R signaling pathway as well as suppresses… 
Review
2012
Review
2012
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
Highly Cited
2011
Highly Cited
2011
Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma
Abstract Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor… 
2011
2011
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry.
2011
2011
Abstract 1276: A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background The incidence of lung cancer has increased… 
2010
2010
Clinical phase I/II study with the insulin-like growth factor-1 receptor inhibitor AXL1717: Future implications for patients with squamous non-small cell lung carcinoma?
e13019 Background: Inhibition of the insulin-like growth factor-1 receptor (IGF-1R) has resulted in extensive antitumor effects… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)